The Predictive Value of the Modified Glasgow Prognostic Score (Mgps) in Determining Outcome Following Elective Colorectal Cancer Surgery

Thomas IM, Amin A, Szczachor J, Rayner S, Wood K and Lim M

Department of General Surgery, Raigmore Hospital, UK

^*Correspondance to: Michael Lim 

 PDF  Full Text DOI: 10.25107/2474-1647.1279

Abstract

Background: The mGPS (modified Glasgow Prognostic Score) provides a measure of systemic inflammation in patients with cancer, based on C-reactive protein (CRP) and Albumin. The aim of this study was to determine the role of mGPS in predicting outcome following elective curative colorectal cancer resections; in terms of survival, stage of disease, likelihood and interval of cancer recurrence.Methods: We in Raigmore Hospital, Inverness have a prospective database of patients undergoing colorectal cancer resections. This database was reviewed between January 2008 and January 2012, yielding 986 patients. Data on pre-operative CRP and Albumin, survival, pathology, and recurrence was collected retrospectively, with patients followed up to 1st February 2015. Patients were classified according to their mGPS score. The mGPS was calculated as follows: CRP< 10mg/L=mGPS 0; CRP >10mg/L or Albumin≤ 35g/L=mGPS 1; CRP >10mg/L and Albumin≤ 35g/L=mGPS 2. Data was found to be parametric and comparisons between mGPS groups were done using the ANOVA test. A p-value of < 0.05 was deemed significant.Results: 387 patients were eligible for inclusion (having had elective curative resections with a calculable mGPS). Survival was significantly different at 45.7, 39.9 and 35.9 months for mGPS groups of 0-2 respectively (p=0.0012). Although there was a trend towards higher TNM staging with rising mGPS, this was not significant (p=0.054). Higher mGPS predicted an increased chance of disease recurrence, with a 17.6% vs. 31.6% vs. 37.1% recurrence rate for mGPS groups of 0-2 respectively. Higher mGPS scores were also associated with a significantly shorter time to recurrence, at 42.3 vs. 34.9 vs. 28.9 months (p=0.0008).Conclusion: The mGPS has value in predicting survival, disease recurrence and time to recurrence in colorectal cancer. The score may be helpful as a decision making tool for the multidisciplinary team.

Keywords

Cite the article

Thomas IM, Amin A, Szczachor J, Rayner S, Wood K, Lim M. The Predictive Value of the Modified Glasgow Prognostic Score (Mgps) in Determining Outcome Following Elective Colorectal Cancer Surgery. Clin Surg. 2016; 1: 1279.